IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332Phase 2/3Active, not recruiting
- Lead sponsor
- IDEAYA Biosciences (Industry)
- Enrollment
- 420 (estimated)
- Start date
- 31 Oct 2023
- Primary completion
- 15 Jan 2027 (estimated)
- Study completion
- 15 Jan 2028
- Last update posted
- 17 Feb 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Sequential
- Masking
- None
- Arms
- 3
Interventions
- IDE196 Drug
- Crizotinib Drug
- Pembrolizumab Drug
- Ipilimumab Drug
- Nivolumab Drug
- Dacarbazine Drug
Conditions and primary outcome
- Metastatic Uveal Melanoma
Primary outcome
Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: (Approximately 5 months); Phase 2 Progression-Free Survival (PFS) (Approximately 2 years); Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment. (Approximately 4 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05987332.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05987332 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.